Ultragenyx Pharmaceutical, Inc.

How big is Ultragenyx Pharmaceutical, Inc.?

As of Jun 18, Ultragenyx Pharmaceutical, Inc. has a market capitalization of $3.47 billion, with net sales of $590.69 million and a net profit of -$549.58 million over the last four quarters. The company has shareholder's funds of $255.30 million and total assets of $1.50 billion as of Dec 24.

Market Cap: As of Jun 18, Ultragenyx Pharmaceutical, Inc. has a market capitalization of 3,465.91 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Ultragenyx reported net sales of 590.69 million and a net profit of -549.58 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company has shareholder's funds amounting to 255.30 million and total assets of 1,503.46 million.

What does Ultragenyx Pharmaceutical, Inc. do?

Ultragenyx Pharmaceutical, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for genetic diseases. As of March 2025, it reported net sales of $139 million and a net loss of $151 million, with a market cap of approximately $3.47 billion.

Overview:<BR>Ultragenyx Pharmaceutical, Inc. is a clinical-stage biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 139 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -151 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 3,465.91 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 2.49 <BR>Return on Equity: -377.52% <BR>Price to Book: 24.03<BR><BR>Contact Details:<BR>Address: 60 Leveroni Ct, NOVATO CA: 94949-5746 <BR>Tel: 1 415 4838800 <BR>Fax: 1 415 4838810 <BR>Website: https://www.ultragenyx.com/

Should I buy, sell or hold Ultragenyx Pharmaceutical, Inc.?

Who are in the management team of Ultragenyx Pharmaceutical, Inc.?

As of March 2022, the management team of Ultragenyx Pharmaceutical, Inc. includes Mr. Daniel Welch as Independent Chairman and Dr. Emil Kakkis as President and CEO, along with several Independent Directors on the Board.

As of March 2022, the management team of Ultragenyx Pharmaceutical, Inc. includes the following individuals:<BR><BR>- Mr. Daniel Welch, who serves as the Independent Chairman of the Board.<BR>- Dr. Emil Kakkis, who is the President, Chief Executive Officer, and a Director.<BR><BR>Additionally, the Board of Directors includes several Independent Directors: Mr. William Aliski, Dr. Deborah Dunsire, Dr. Lars Ekman, Mr. Matthew Fust, and Mr. Michael Narachi.

Is Ultragenyx Pharmaceutical, Inc. overvalued or undervalued?

As of February 20, 2018, Ultragenyx Pharmaceutical, Inc. is considered risky and overvalued due to its high Price to Book Value of 24.36, negative EV to EBITDA of -8.10, and poor ROE of -377.52%, alongside significant underperformance against the S&P 500 with a YTD return of -30.81%.

As of 20 February 2018, the valuation grade for Ultragenyx Pharmaceutical, Inc. moved from does not qualify to risky, indicating increased concerns regarding its financial health. The company appears to be overvalued, given its high Price to Book Value of 24.36 and negative EV to EBITDA of -8.10, alongside a troubling ROE of -377.52%. In comparison to its peers, Madrigal Pharmaceuticals has a significantly worse P/E ratio of -35.88, while Corcept Therapeutics is categorized as very expensive with a P/E of 60.03, highlighting the relative valuation challenges Ultragenyx faces.<BR><BR>The company's stock has underperformed against the S&P 500 across multiple periods, with a staggering YTD return of -30.81% compared to the index's 12.22%. This trend of underperformance reinforces the notion that Ultragenyx is currently overvalued in the market.

Is Ultragenyx Pharmaceutical, Inc. technically bullish or bearish?

As of September 26, 2025, Ultragenyx Pharmaceutical, Inc. shows a mildly bearish trend with mixed indicators, underperforming the S&P 500 with a year-to-date return of -30.88% compared to 12.96%.

As of 26 September 2025, the technical trend for Ultragenyx Pharmaceutical, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The weekly MACD is mildly bullish, while the monthly MACD remains bearish. The weekly RSI indicates bullish momentum, but the monthly RSI shows no signal. Moving averages on a daily basis are mildly bearish, and both the KST and Dow Theory indicate bearish trends on a monthly basis. <BR><BR>In terms of returns, the stock has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -30.88% versus the S&P 500's 12.96%, and a one-year return of -47.34% compared to 15.64% for the index.